Event-free survival as a predictor of overall survival and recurrence burden of patients with non–small cell lung cancer receiving neoadjuvant therapy-Reference-Cited by-同舟云学术

Event-free survival as a predictor of overall survival and recurrence burden of patients with non–small cell lung cancer receiving neoadjuvant therapy

Published:2023-12 Issue: Volume: Page:
ISSN:0022-5223
Container-title:The Journal of Thoracic and Cardiovascular Surgery
language:en
Short-container-title:The Journal of Thoracic and Cardiovascular Surgery

Author:

Donington Jessica,Hu Xiaohan,Zhang Su,Song Yan,Arunachalam Ashwini,Chirovsky Diana,Gao Chi,Lerner Ari,Jiang Anya,Signorovitch James,Samkari Ayman

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

Reference28 articles.

1. Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis;Melosky;Mol Diagn Ther,2022

2. The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer;Chansky;J Thorac Oncol,2017

3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines) for non-small cell lung cancer. V.3.2023,2023

4. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer;Forde;N Engl J Med,2022

5. 1235TiP Perioperative pembrolizumab+ platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: the phase III KEYNOTE-671 study;Tsuboi;Ann Oncol,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Percentage” and “size” of residual viable tumor in lymph node, the performance in estimating pathologic response of lymph node in non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy;Human Pathology;2024-07

2. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials;Frontiers in Immunology;2024-04-05

3. Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy;Annals of Diagnostic Pathology;2024-04